As the inaugural African Medicines Agency (AMA) Week unfolds in Kigali, African governments face a clear call to strengthen the institution established to protect their populations. So far, 34 of the African Union's 55 Member States have ratified the AMA Treaty.
The remaining countries should make ratification a national priority.
Rwanda, which hosts the headquarters of AMA, is among countries that have already shown that commitment. It became the first African Union Member to ratify the Treaty in 2019.
Keep up with the latest headlines on WhatsApp | LinkedIn
The appeal to ratify the AMA Treaty has come strongly from participants, including WHO Director-General Dr Tedros Adhanom Ghebreyesus, Rwanda's Minister of State for Health Dr Yvan Butera, AMA Special Envoy Dr Michel Sidibé and Chad's Secretary of State for Health Dr Francine Dekandji. Their message has been that Africa needs broader participation in a regulatory system capable of serving its collective health interests.
Developments at AMA Week give substance to that appeal. The inauguration of seven technical committees and the launch of two regulatory hubs provide practical mechanisms for pooling scientific expertise, strengthening national regulators and helping manufacturers meet requirements for quality, safety and efficacy.
These capabilities address a costly weakness. Fragmented regulatory processes require scarce expertise to be deployed repeatedly on the same products. Duplication consumes resources, creates uncertainty for manufacturers and can delay access to treatment. Sharing rigorous scientific assessments allows countries to use their capacity more effectively.
Ratification is therefore an investment in stronger national institutions. AMA was created to strengthen the capacity of countries to regulate medicines, vaccines, medical devices, and other therapeutics thereby expanding access to safe and quality medical products.
The manufacturing case is equally compelling. Africa's ambition to produce more medicines, vaccines and diagnostics requires credible, predictable regulation alongside factories and financing. AMA's manufacturing readiness hub can help innovators understand regulatory requirements earlier, while greater coordination can make access to African markets more manageable.
Patients must remain the ultimate measure of success through stronger protection against unsafe and falsified products, better safety monitoring and more timely access to quality-assured treatments.
Ratification alone will not achieve this. Governments must support implementation and invest in national regulatory capacity. AMA must demonstrate scientific independence, transparency and measurable results.
National ratification procedures deserve respect, but the costs of fragmentation demand urgency. Governments still outside the Treaty should now establish clear pathways to joining it. Africa's health security requires sustained commitment from every Member State.